Related Experiment Video
Updated: Mar 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Model-Driven Paediatric Cardiomyopathy Pathways - A Clinical Impact Assessment.
Karl A Stroetmann1, Rainer Thiel1
1empirica Communication & Technology Research, Bonn, Germany.
This study developed a simulation model for pediatric cardiomyopathy, finding that while a clinical decision support tool may slightly increase initial costs, it offers significant long-term benefits in saved life years and improved quality of life.
Area of Science:
- Pediatric Cardiology
- Health Technology Assessment
- Computational Modeling
Background:
- Paediatric cardiomyopathy and heart failure pose significant clinical challenges.
- Existing treatment options require comprehensive data for effective pathway modeling.
- Accurate prognostication is crucial for managing pediatric heart conditions.
Purpose of the Study:
- To report intermediate results from a health technology assessment of a simulation model for paediatric cardiomyopathy.
- To develop and validate a detailed clinical pathway model for paediatric cardiomyopathy.
- To compare standard care with a novel clinical decision support tool using simulation.
Main Methods:
- Collected comprehensive data on paediatric cardiomyopathy, treatments, incidence, prevalence, and prognoses.
- Developed a clinical pathway model integrating disease stages, treatments, and transition probabilities.
- Employed a Markov decision process combining a three-stage Markov model and decision trees.
- Utilized a Markov Chain simulation tool for a ten-year cohort analysis.
Main Results:
- Early results show a slight increase in overall costs due to the decision support tool.
- Expected savings from improved care are anticipated.
- The model simulates transition probabilities and cost data for standard care versus the new tool.
Conclusions:
- The clinical decision support tool may incur initial cost increases.
- Intangible benefits, such as increased life years for severely ill children, are expected.
- Improved quality of life for moderately ill children is a key anticipated outcome, potentially outweighing costs.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

